Abstract
Background Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are routinely tested and reported; however, Trichomonas vaginalis (TV) is the most common STI in the US and the prevalence of Mycoplasma genitalium (MG) infections is likely higher than estimated. We examined the clinical performance of the Alinity m STI assay for detection and surveillance of CT/NG/TV/MG in urine specimens from patients at a large academic medical center.
Methods Prevalence of mono- and co-infections on Alinity m STI pathogens and predictors of a positive result were identified. Alinity m STI and Aptima Combo 2 CT/NG and TV assay (Panther System) results were compared, with discrepant results run on the cobas 6800 CT/NG, TV and MG assays. Analyzer turnaround times (TAT) were determined for Alinity m and Panther systems.
Results 199 urine specimens were included. Age ≥25 years, collection outside the emergency department (ED), and asymptomatic status were predictive of TV or MG infection; symptomatic status was the only predictor of CT or NG infection. Overall agreement rates for the Alinity m, Aptima, and cobas assays ranged from 86.4% to 99.5% for the four pathogens. TV and MG infections comprised 54% of the positive samples and were more often asymptomatic than CT and NG infections. Analyzer TAT (onboard to result reporting) was 4 hours 45 minutes for the Aptima CT/NG, 3 hours 25 minutes for Aptima TV, and 1 hour 55 minutes for Alinity m STI assay.
Conclusions The Alinity m STI assay allows for fast and simultaneous detection of the four major STI pathogens, which can facilitate surveillance and provide accurate results to help clinicians diagnose for initiation of appropriate treatment.
Competing Interest Statement
Joshua Kostera is an employee of Abbott Laboratories. This study was funded by a grant from Abbott Laboratories.
Funding Statement
This study was funded by Abbott Laboratories.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted following GCLP and in accordance with the Declaration of Helsinki, under WCG IRB# 1301043.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of Interest and Source of Funding Joshua Kostera is an employee of Abbott Laboratories. This study was funded by a grant from Abbott Laboratories.
Summary Evaluation of Alinity m STI clinical performance for diagnosis and surveillance of CT, NG, TV, and MG in a large academic medical center in the US.
Data Availability
All pertinent data produced in the study are included in the manuscript.
